| Acute recurrent diverticulitis is prevented by oral administration of a polybacterial lysate suspension. | |
| | |
MedLine Citation:
|
PMID: 15722985 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
AIM: The main cause of acute diverticulitis is the abnormal accumulation of fecal bacteria within the diverticular lumen, leading to a balancing between normal probiotic microflora and pathogenic species; Gram negative Entero-bacteriaceae, mainly Escherichia coli and Proteus spp, are the genders that usually cause the disease-related symptoms, due to their ability to adhere to intestinal mucosa. The intestine is well known as the largest human lymphoepithelial organ and daily produces more antibodies, mainly secretory IgAs, than do all other lymphoid tissues. IgAs have different immune and anti-inflammatory properties. The aim of this study was to verify the efficacy of an oral immunostimulant highly-purified, polymicrobial lysate in the prevention of recurrent attacks of diverticulitis and in the improvement of symptoms. METHODS: The study was carried out on 83 consecutive patients suffering from recurrent symptomatic acute diverticulitis and with at least 2 attacks in the previous year; patients were randomly assigned to receive (group A) an oral polybacterial lysate suspension or to a no-treatment clinical follow-up as controls (group B). RESULTS: A total of 76 patients (41 in group A and 35 in group B) terminated the study period. the sums of the scores for symptoms, reported on day schedules, were calculated and examined by means of ANOVA statistical analysis. Statistical differences between group A vs group B were recorded after 1 month (p<0.05) and 3 months (p<0.01) of treatment with the oral polybacterial lysate suspension. CONCLUSIONS: Our data suggest that the administration of an oral enterovaccine for the prophylaxis of recurrent diverticulitis is effective and well tolerated, probably due to a direct stimulation of IgA-mediated mucosal defences. |
| | |
Authors:
|
L Dughera; A M Serra; E Battaglia; D Tibaudi; M Navino; G Emanuelli |
Related Documents
:
|
8359165 - Meropenem versus imipenem/cilastatin in the treatment of intraabdominal infections requ... 12897315 - Vancomycin use in hospitalized pediatric patients. 10423465 - Oral versus intravenous empirical antimicrobial therapy for fever in patients with gran... 19119075 - Methicillin resistant staphylococcus aureus endocarditis in an australian tertiary hosp... 8917255 - Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angiopla... 10201585 - Combined phacoemulsification and goniosynechialysis for uncontrolled chronic angle-clos... |
Publication Detail:
|
Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial |
Journal Detail:
|
Title: Minerva gastroenterologica e dietologica Volume: 50 ISSN: 1121-421X ISO Abbreviation: Minerva Gastroenterol Dietol Publication Date: 2004 Jun |
Date Detail:
|
Created Date: 2005-02-21 Completed Date: 2005-03-11 Revised Date: 2012-06-22 |
Medline Journal Info:
|
Nlm Unique ID: 9109791 Medline TA: Minerva Gastroenterol Dietol Country: Italy |
Other Details:
|
Languages: eng Pagination: 149-53 Citation Subset: IM |
Affiliation:
|
Digestive Motility and Endoscopy Unit, Department of Clinical Physiopathology, University of Turin, Turin, Italy. luca.dughera@libero.it |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Acute Disease Adjuvants, Immunologic / administration & dosage* Administration, Oral Aged Analysis of Variance Anti-Infective Agents / administration & dosage, therapeutic use Bacteria Bacterial Vaccines / administration & dosage* Cell Extracts / administration & dosage* Chi-Square Distribution Ciprofloxacin / administration & dosage, therapeutic use Colonoscopy Diverticulitis / diagnosis, drug therapy, immunology, microbiology, prevention & control*, therapy Diverticulitis, Colonic / diagnosis, drug therapy, immunology, microbiology, prevention & control, therapy Female Follow-Up Studies Gastrointestinal Agents / administration & dosage, therapeutic use Humans Injections, Intravenous Intestinal Mucosa / immunology Male Middle Aged Recurrence Rifamycins / administration & dosage, therapeutic use Time Factors |
| Chemical | |
Reg. No./Substance:
|
0/Adjuvants, Immunologic; 0/Anti-Infective Agents; 0/Bacterial Vaccines; 0/Broncho-Vaxom; 0/Cell Extracts; 0/Gastrointestinal Agents; 0/Rifamycins; 85721-33-1/Ciprofloxacin; 88747-56-2/rifaximin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: What do heartburn sufferers expect from proton pump inhibitors when prescribed for the first time?
Next Document: Intestinal permeability assessment before and after ileal pouch-anal anastomosis.